Upload
elsa-simangunsong
View
221
Download
0
Embed Size (px)
Citation preview
8/7/2019 Asthma Clinical Guide
1/29
Building Healthy Lifestyles
Chronic Respiratory
AsthmaClinical Guide
Building
Lifestyles
Healthy1-866-506-6654
388-6654
8/7/2019 Asthma Clinical Guide
2/29
Asthma
Building Healthy LifestylesChinook Health Region 2
We would like to acknowledge the contribution of the following groups:
Chronic Respiratory Interdisciplinary Working Group
Chronic Disease Physician Advisory Group
Chronic Disease Clinical Leadership Group
Specialist Consultants
Chronic Respiratory Clinical Champions
CHR Asthma Program Committee
Utilizing the Chronic Care model, these groups developed the Asthma Clinical Guide as a decision-support tool for improved functional and clinical outcomes. is Guide supports primary care
interdisciplinary team-based practice with a strong focus on self-management.
Please use and reproduce with acknowledgement to the Chinook Health Region.
Chronic Disease Management and Prevention Network:An Alberta Health Capacity Building Initiative
Chinook Health RegionLethbridge, Alberta
April 2006
8/7/2019 Asthma Clinical Guide
3/29
Asthma
Building Healthy LifestylesChinook Health Region 3
Table of Contents
1. Diagnosis
a. Definition ............................................................................................................5b. Risk Factors .........................................................................................................5c. Screening .............................................................................................................6d. Signs and Symptoms ............................................................................................6e. Testing and Evaluation ........................................................................................6f. Further Testing ....................................................................................................7g. Algorithm ............................................................................................................8
2. Classification/Type/Staginga. Stages/Types of Disease ........................................................................................11
3. Patient Care Flow Sheet for Health Teams
a. Patient Care Flow Sheet ......................................................................................13b. Key Clinical Summary .........................................................................................14
4. Management Strategies for Health Teamsa. Goals of Management ..........................................................................................15b. Key Clinical Targets .............................................................................................15c. Non-Pharmacologic Strategies .............................................................................15d. Pharmacologic Strategies......................................................................................16
5. Management Strategies for Patients/Clientsa. Self-Care Support Information/Handouts/Tools .................................................21b. Patient/Client Checklist for Evidence-Based Care ................................................25
6. Referral to Specialists/Specialty Programa. Indications for Referral to Medical Specialists ......................................................27b. Indications for Referral to Specialty Programs ......................................................27c. Local Contacts .....................................................................................................27
7. Referencesa. Evidence ..............................................................................................................29b. On-line Resources ...............................................................................................29c. Supplementary Handouts Available .....................................................................29
8/7/2019 Asthma Clinical Guide
4/29
Asthma
Building Healthy LifestylesChinook Health Region 4
8/7/2019 Asthma Clinical Guide
5/29
Asthma
Building Healthy LifestylesChinook Health Region 5
1. Diagnosis
BUILDING HEALTHY LIFESTYLESCHRONIC RESPIRATORY-ASTHMA
Unless clinical practice guidelines are followed, the danger of bothunder- and over-diagnosis exists. e interpretation and availabilityof tests to assess variable airway obstruction is inconsistent. Becauseof the variable nature of the disease over time, the tests for airwayobstruction and hyper-responsiveness may not reveal a problem evenwhen asthma exists.
1. Diagnosis
a. Definitions:
Asthma: is characterized by paroxysmal or persistent symptomssuch as dyspnea, wheezing, chest tightness, sputum production andcough associated with variable airflow limitation and airway hyper-responsiveness to endogenous or exogenous stimuli.
Exercise Induced Bronchospasm (EIB): is a reversible airwayobstruction that occurs during or after strenuous physical exertion.Solitary EIB is not asthma and it is important to distinguish if exerciseinduced symptoms are the result of poorly controlled asthma.
EIB versus Asthma
A therapeutic trial is a practical way to confirm EIB. e clienttakes B-2 agonists, 15 minutes prior to exercise; the EIB diagnosis isconfirmed if the medications prevent or diminish symptoms. echallenge is to distinguish whether or not the patient has asthma
with an exercise exacerbation or has solitary EIB. Because treatmentis different for these two conditions, it is important to evaluatethe patient for asthma using patient history, physical exam andpulmonary function tests (spirometry).
Occupational Asthma (OA) is asthma induced by exposure to aspecific agent in the workplace; is the most common occupationallung disease in developed countries. OA has been estimated to cause5 15 % of adult onset asthma.
An occupational cause should be suspected for all new cases ofasthma in adults
Temporal associations are not sufficient to diagnose work-related
asthma and objective tests are required to confirm the diagnosis.Workers with asthma symptoms should not be told to leave theirjob until diagnosis is proven because part of the diagnostic work-up of OA may involve a return trial to work.
Referral to a medical specialist for evaluation of OA
Irritant-induced Asthma is caused by single or multiple exposuresto high concentrations of an irritant vapour, fume or smoke in peoplewho have no previous diagnosis or history of asthma symptoms. Teterm Reactive airways dysfunction syndrome or RADS is used
when the condition is caused by a single exposure.
Reactive Airways Disease (RADS) is poorly defined, confusing andshould not be used in lieu of possible or probable Asthma.
b. Risk Factors
Major risk factors:i. Personal history of atopy, especially atopic dermatitisii. Parental history of asthma or eczemaiii. ree or more episodes of wheeze during the first three years
of life
Minor risk factors:i. Eosinophiliaii. Wheezing without colds
iii. Allergic rhinitisiv. Environmental tobacco smoke (ETS)
OCCUPATIONAL ASTHMA (OA)
Highest risk occupations and asthma-producing substances
OCCUPATION ASTHMA-PRODUCINGSUBSTANCES
Adhesive handlers Chemicals such as acrylate
Animal handlers, vets, researcher Animal proteins
Bakers, Millers Cereal Grains
Carpet makers Gums
Electronic workers Soldering resin
Forest workers, Carpenters,Cabinet makers
Wood dust
Hairdressers Chemicals such as persulfate
Healthcare professionals Latex and chemicals such asglutaraldehyde
Janitors, Cleaning staff Chemicals such as chloramine-T
Pharmaceutical workers Drugs, enzymes
Seafood processors Seafood
Shellac handlers Chemicals such as amines
Solderers, Refiners Metals
Spray painters, Insulationinstallers, Plastic & Foamindustry workers
Chemicals such as diisocyanates
Textile workers Dyes
Users of plastics, epoxy resins Chemicals such as anhydrides
8/7/2019 Asthma Clinical Guide
6/29
Asthma
Building Healthy LifestylesChinook Health Region 6
1. Diagnosis
c. Screening
ere is currently no organized approach to screening for asthma inCanada.
d. Signs and Symptoms
Asthma
Coughing
Wheezing
Chest tightness
Shortness of breath
Trouble sleeping because of breathing difficulty
Reduced physical activity due to breathing difficulty
EIB:
Coughing, wheezing, shortness of breath and chest tightness
immediately following 6 to 8 minutes of strenuous exercise.ese symptoms may occur during or after exercise.
e. Testing and Evaluation
Evaluation and diagnosis of asthma in clients able to performlung function tests (Usually 6 years of age and older):
ere is no one definitive test that can be used to diagnose asthma,requiring the bringing together of many sources of information inorder to reach such a diagnosis. At the present time, diagnosingasthma is based on the following:
the presence of typical symptoms of asthma and an improvement
in these symptoms with asthma medication evidence of variable airflow limitation and/or obstruction
in some circumstances, evidence of hyper-responsiveness of theairways using a provocation challenge test
Steps in primary care setting to accurately diagnosis asthma, suspectasthma based on symptoms, physical exam and patient history.Next, confirm diagnosis through lung function tests showingvariable airflow obstruction and/or response to trial of asthmamedications.
orough history: covering symptoms and pattern of symptomsas well as what triggers the symptoms. Personal history of atopy
(eczema, hay fever, hives, allergic rhinitis, allergies) and familyhistory of atopy or asthma in close relatives.
Physical exam: should focus on upper respiratory airway(nasopharynx) and lower respiratory airway (chest) as well asthe skin. Physical exam may help confirm the diagnosis ofasthma, but does not generally provide the diagnosis. Physicalexam alone tends to underestimate the severity of an asthmaexacerbation. Co-morbid conditions such as rhinitis, sinusitis,post nasal drip or Gastroesphageal Reflux Disease (GERD) thatmimic or worsen asthma symptoms should be evaluated andaddressed.
Findings with asthma that may be present are: use of accessory muscles of respiration tracheal tug indrawing hyperinflation of the chest decreased air entry
prolonged expiration wheezing wheeze with forced expiration silent chest
Lung function tests (2 types): Objective measurements areneeded to confirm the diagnosis of asthma and to assess itsseverity accurately in all symptomatic patients.
i. Spirometry (preferred method)- A 12% (at least 180 mL in adults) or greater improvement in
Forced Expiratory Volume (FEV)1.0 15 minutes (10 minutesis more practical and used in the LRH PFT lab) after use ofan inhaled short-acting beta-2 agonist will confirm diagnosis
of asthma*- A 20% (at least 250mL in adults) or greater improvement in
FEV1.0 after 10-14 days of inhaled glucocorticosteriods oringested prednisone, when symptoms are stable will confirmdiagnosis of asthma
- A 20% (at least 250 mL in adults) or greater spontaneousvariability in FEV1.0 over time is considered significant and
will confirm the diagnosis of asthma
ii. Peak Expiratory Flow or PEF (used when spirometry isunavailable or home monitoring is required to diagnose)
- Variable airflow obstruction can be documented by homemeasured PEF that shows a 20% or greater diurnal variability
over a period of several weeks. is can confirm thediagnosis of asthma.
- A 20% or greater improvement in PEF, 15 minutes (10minutes is more practical) after the administration of a shortacting beta-2 agonist may be used to confirm asthma in aphysicians office when spirometry is not available.
- Both these methods are not as reliable as spirometry.
erapeutic trial of asthma medications, which should includeInhaled Corticosteroids (ICSs) daily and short-acting B-2 agonistas needed for a period of 2-4 weeks may be helpful in confirmingthe diagnosis of asthma.
Evaluation and diagnosis of asthma in clients unable to performlung function tests (Usually less than 6 years of age):
NOTE: ere are no age criteria for the diagnosis of asthmaas it can be diagnosed at any age. However, caution should beused when diagnosing asthma in clients less than one year ofage. Persistent respiratory symptoms in infants and children may
warrant a referral to a specialist.
e diagnosis rests on careful and sometimes repeated historytaking and physical examination as stated above
*Please note- in children age 6-17 only a 12% improvement in FEV 1.0 isrequired after bronchodilator.
8/7/2019 Asthma Clinical Guide
7/29
Asthma
Building Healthy LifestylesChinook Health Region 7
1. Diagnosis
Factors particularly useful in establishing a diagnosis in youngpatients: severe episodes of wheezing wheezing after 1 year of age more than 3 episodes of wheezing in a given year family history of asthma/atopy
personal history of asthma/atopy maternal smoking clinical benefits from acute bronchodilator therapy clinical evidence of improvement after anti-inflammatory
treatment chronic cough (especially nocturnal or associated with
exercise) wheezing when viral etiology is unlikely
e likelihood of a diagnosis of asthma increases with the numberof these factors present.
Clinical Index for the Diagnosis of Asthma
Stringent Index: 3 or more episodes of wheeze during the first3 years of life with either one of the major riskfactors: parental history of asthma or eczema, or2 of 3 minor risk factors; eosinophilia, wheezing
without colds, allergic rhinitis
Loose Index: any wheezing during the first 3 years of life plus 1major or 2 minor risk factors
Clinical Clues to Alternate Diagnosis
Not asthma: poor response to therapy after ensuring compliancewith trigger avoidance strategies, proper inhaler use and compliance
with medical treatment. No history of atopy. Cystic fibrosis: malabsorption, finger clubbing, nasal polyps
Pertussis: paroxysmal cough, ill contacts
Rhinitis/Sinusitis: no wheeze, throat clearing
Gastroesophageal Reflux (GER): previous regurgitation, nighttime
Congenital malformation: age under one year
Foreign Body: sudden onset without Upper Respiratory Infection(URI), focal findings
f. Further Testing
Referral to a medical specialist for bronchoprovocation testing tohelp confirm or rule out asthma.
Appropriate allergy assessment is warranted in patients withasthma and must be interpreted in light of patients history.
Allergen exposure is a risk factor for severe, acute asthma,especially if the patient is exposed to high concentrations ofthe specific allergen. erefore, allergens to which a personis sensitized should be identified through allergy testing.Once identified, steps should be taken to eliminate or at leastsubstantially reduce allergen exposure.
8/7/2019 Asthma Clinical Guide
8/29
Asthma
Building Healthy LifestylesChinook Health Region 8
1. Diagnosis
g. Algorithms
Approach to Asthma Diagnosis in Clients Able to Perform Spirometry Tests
Reliably (usually 6 years of age or greater) in the Primary Care Setting
Suspect asthma based on symptoms, patient history & physical exam
Confirm diagnosis of asthma with Pre & Post Spirometry Testing
Is there a >12% improvement in Forced ExpiratoryVolume FEV1.0 (of at least 180ml in adults 18+) 10 YES
minutes after short-acting bronchodilator*
Asthma diagnosis confirmedInitiate treatment & asthma education(Referral to asthma educator)
Does pre & post spirometry test meet the following criteria to be considered normal FEV1.0/FVC ratio > 0.7 FVC > 80% of predicted value FEV1.0 > 80% of predicted value
NO
If FVC is < 80% predicted andFEV1.0/FVC ratio is > 0.7
Post bronchodilator FEV1.0/FVCratio is < 0.7bronchodilator FEV1.0 is < 80%predicted
If post bronchodilatorFEV1.0/FVC ratio is < 0.7
Consider diagnosis of restrictivelung defect not consistent with adiagnosis of asthma - referral to aspecialist may be warranted
Diagnosis of COPD can beconfirmed alone or co-existing withasthma
Consider diagnosis of irreversibleobstructive lung defect
Is client currently symptomatic
YES NO
and post
Initiate proper COPD treatment
Initiate proper asthma therapy ofinhaled corticosteroids and short-acting bronchodilators for one monththen follow up and reassess
Repeat spirometry if and whensymptoms recur to confirmdiagnosis of asthma or dismissdiagnosis of asthma
YES NO
Clinical benefits after proper asthmatherapy?
Asthma diagnosis may be confirmedConsider re-test with spirometryInitiate treatment and asthmaeducation (referral to an asthmaeducator)
Referral to a specialist for bronchoprovocation testing to help confirm / rule out diagnosis of asthand investigate other conditions that mimic asthma (i.e. Gastroesophageal Reflux Disease (GEvocal cord dysfunction)
Notes:
FVC is forced vital capacity, FEV1.0 is forcedexpiratory volume in 1 second.
Normal predicted values in spirometry are availablefor people 5 years of age and older. No normalpredicted values exist for children younger than 5
years of age. Some children as young as 5 can givereliable spirometry testing. Therefore, this may needto be decided by the person performing the test.
*
NO YES
In children age 6 - 17 only a 12% improvement in
FEV1.0 10 minutes after a short-acting bronchodilator
is required to confirm a diagnosis of asthma.
8/7/2019 Asthma Clinical Guide
9/29
Asthma
Building Healthy LifestylesChinook Health Region 9
1. Diagnosis
Approach to Asthma Diagnosis in Clients Able to Perform Peak Expiratory Flow TestsReliably (usually 6 years of age or greater) in the Primary Care Setting
Suspect asthma based on symptoms, patient history & physical exam
Spirometry is not available
(Spirometry is the preferred method according to the CPGs)
Confirm Diagnosis of asthma with Peak Expiratory Flows (PEF)
YES NO YES
Is client currently symptomatic
YES
YES NO
Note: PEF is less reliable than spirometry for confirming the diagnosis of asthmaTo calculate a 20% improvement in PEF following administration of a short-acting B-2 agonist:
1. Obtain a peak flow reading prior to medication, e.g. 400 lpm2. Multiply that number by 1.2 to give value needed to confirm a 20% improvement in PEF (400 x 1.2 = 480).3. Give B-2agonist, wait 10 minutes then repeat PEF; this value must be > 480 lpm to show a 20% improvement in
PEF and confirm diagnosis of asthmaTo calculate diurnal variation of PEF:
1. Client is to measure peak flows in the am and pm of each day for 2-4 weeks and record the best value of 3 triesin a diary
2. Once this data has been recorded, calculate the diurnal variation of each day by using the following formula:Highest PEF Lowest PEF (on the same day) x 100
Highest PEFFor example: Day 1 Day 2 Day 3
PEF am pm am pm am pm400 500 400 450 350 500
500 400 x 100 450 400 x 100 500 350 x 100500 450 500
= 20% diurnal variation = 11.1% diurnal variation = 30% diurnal variation Children as young as 5 years of age may be able to properly perform PEF. There are no predicted values for childrenunder 5 years of age for peak flow.
>20% improvement in PEF 10 minutes afteradministration of short-acting B-2 agonist
>20% or greater diurnal variability in PEFover a period of several weeks
Asthma diagnosis confirmedInitiate treatment and asthma education
(referral to an asthma educator)
Asthma diagnosis confirmedInitiate treatment and asthma education
(referral to an asthma educator)
Initiate proper asthma therapy of inhaledcorticosteroids and short-acting bronchodilatorsfor one month then follow up and reassess
Repeat PEF if and when symptoms recur
Clinical benefits after proper asthma therapy
Asthma diagnosis may be confirmedConsider retesting with spirometryInitiate treatment and asthmaeducationConsider a referral to an asthmaeducator
Consider a referral to have pre & post spirometry done or referral to aspecialist for bronchoprovocation test to help confirm / rule outasthma diagnosis and investigate other conditions that mimic asthma(i.e. Gastroesophageal Reflux Disease (GERD), vocal corddysfunction).
8/7/2019 Asthma Clinical Guide
10/29
Asthma
Building Healthy LifestylesChinook Health Region 10
1. Diagnosis
Approach to Asthma Diagnosis in Clients Unable to Perform Reliable
Pulmonary Function Tests (less than 6 years of age) in the Primary Care Setting
Suspect asthma based on symptoms, patient history & physical exam
First, determine the presence of airway sensitivity by inquiring about symptoms such as cough,wheeze, limited physical activity, chest tightness and shortness of breath.
Second, look for evidence of inherited ability to react to stimuli - is there a family history of atopyand a personal history of eczema or atopy.
Third, establish that there is no underlying lung disease - look for anything else that could becausing cough.
Therapeutic trial of asthma medications to confirm diagnosis of asthma in preschool children
OR
Reassess response to asthma therapy in child Did Beta-2 agonist provide relief from wheeze, chest tightness and SOB? Did cough subside after one month of inhaled corticosteroids? Did cough subside after 5 days of oral prednisone?
YES NO
NOTE- there is no age criteria for the diagnosis of asthma as it can be diagnosed at any age. However,caution should be used when diagnosing asthma in children less than one year of age. Persistentrespiratory symptoms in infants and children may warrant a referral to a specialist.
Asthma diagnosis may be confirmedespecially if symptoms recur whenmedications are stoppedInitiate treatment and asthma educationReferral to an asthma educator
Consider an alternate diagnosisConsider a referral to a Pediatrician
Beta-2 agonists for relief of symptoms such as wheeze, chest tightness and shortness of breath (SOB)
AND
Inhaled Corticosteroid for coughing for a period of one month
Oral prednisone for therapeutic trial for coughing, 1mg/kg per day up to a maximum of 50 mg x 5 days
CAUTION: ensure child is not incubating varicella virus. A comprehensive varicella history should bedone
8/7/2019 Asthma Clinical Guide
11/29
Asthma
Building Healthy LifestylesChinook Health Region 11
2. Classification/Type/Staging
2. Classification/Type/Staging
Determining the Severity of Asthma
Assessment of asthma severity will help physician determineappropriate level of therapy required, as well as when a client
should be referred to a specialist.
e severity of asthma can be evaluated in two ways:
1. Before or without treatment which takes into accountsymptoms, physiological indicators of airway disease (lungfunction tests) and morbidity.
2. With treatment or when controlled asthma amount ofmedication required to maintain control.
e primary measure of asthma severity in the treated patientshould be the minimum therapy required to achieve acceptablecontrol.
8/7/2019 Asthma Clinical Guide
12/29
Asthma
Building Healthy LifestylesChinook Health Region 12
2. Classification/Type/Staging
Asthma severity before or without proper treatment
Event or measurement Mild Moderate Severe
FEV1.0 or PEF, % of predicted >80% 60 79%
8/7/2019 Asthma Clinical Guide
13/29
Asthma
Building Healthy LifestylesChinook Health Region 13
Asthma Patient Care Flow Sheet Patient Name
Comorbid Conditions PHN
Year of Diagnosis
DATE: _________ _________ _________ ________ _________ _________
REVIEW ITEMSNeeds reliever medication 4 times/week(may use 1 dose/day for exercise)
Physical activity limited by symptoms (in past 3 months)(Sx: coughing, wheezing or chest tightness)
Symptoms wake patient at night 1 times/week
Symptoms 4 days/week
Any urgent visits for asthma since last regular appointment
Absence from work/school because of asthma
(in last 3 months)
lortnoCamhtsA
*Client must answer all with NO to have Control , if Yes to one or more questions asthma is not controlled reassess
Smoker or secondhand smoke in the home/vehicles. If yesaddress smoking (ask, advise, assist, arrange 4As)
Identified asthma triggers:
Have steps been taken to reduce exposure to asthma triggers
ecnadiovAreggirT
A client that is not reducing exposure to allergens and asthma triggers will be difficult to control. Referral to asthma program
Does client have a written asthma action plan
* If not, provide a written CHR asthma action plan
Client understands how to use the asthma action plan
Is controller medication used regularly?Controller medications:
Reliever Medications:
Economic Concerns (cost of meds):
ecnailpmoC
Have patient demonstrate how they use their inhaler device(s)
*Ensure Proper Inhaler Technique
Sx of GERD, Rhinitis, Sinusitis
Asthma meds that may affect other diseases
(Prednisone use, test blood glucose)
Sx of depression, anxiety
ISIV
ECIFFO
RALUGER
AMHTSA
ROF
ST
seitidibromo
C * If any comorbidities exist with asthma, treat appropriately as these may affect proper asthma control
Perform Pre & Post Spirometry testing yearly & prnstseT
Height and weight (especially for pediatrics)BMD for osteoporosis (If on ICSs and has risk factors)
Review asthma action plan, try to reduce medication required
while maintaining asthma control
Referrals: Asthma educatorfor education & evaluation
for initial education & follow up as needed
Medical Specialist as needed
YLLAUNNA
tnemeganaM
Vaccinations: Annual Influenza vaccine
Pneumoccocal vaccine if > 65 years
Immunizations up to date
Revised as of May 9, 2005 developed by the BHL/chronic respiratory/ Chinook Health Region
3. Chronic Disease Patient Care Flow Sheet
3. Chronic Disease Patient Care Flowsheet
8/7/2019 Asthma Clinical Guide
14/29
Asthma
Building Healthy LifestylesChinook Health Region 14
3. Patient Care Flow Sheet
Asthma Continuum of Care Reliever (Rescue) medications Salbutamol (Ventolin) MDI 100 mcg per dose 1 or 2 inhalations as needed Salbutamol (Ventolin) Diskus 200 mcg per dose
Adults & children 6 and older, 1 inhalation as needed
Terbutaline (Bricanyl) Turbuhaler 0.5 mg per dose
Adults & children 6 and older, 1 inhalation as needed
Salbutamol (Airomir) MDI 100 mcg per dose 1 to 2 inhalations as needed
Inhaled Corticosteriods (Preventer/controller medications)ICSs should be introduced as the initial maintenance treatment for asthma,even in subjects who have very mild asthma and use their relievermedication less than 3 times/week. Refer to chart on left for proposeddoses for ICSs Fluticasone (Flovent) MDI 50, 125 & 250 mcg per dose
BID dosing most effective Fluticasone (Flovent) Diskus 50, 100, 250, 500 mcg per dose BID dosing most effective Budesonide (Pulmicort) Turbuhaler 100, 200 & 400 mcg per dose BID dosing most effective
Daily Long Term Inhaled Steroid Agents and Doses Beclomethasone (Q-var) MDI 50 & 100 mcg per dose BID dosing most effective
Add on Therapy if requiredIf asthma is not controlled by low doses of ICSs, additional therapyshould be considered:FIRST OPTION Add long-acting beta2 agonist to existing therapy ofICSs and short-acting beta 2 agonists, or replace ICSs with a combinationmedication. Salmeterol (Serevent) MDI 25 mcg per dose Adults 1 or 2 inhalations BID
Children 4 years of age and older 1 or 2 inhalations BID Salmeterol (Serevent) Diskus 50 mcg per dose
Adults 1 inhalation BIDNote: children will auto scale their inhaled medication dose, (take Children 6 years of age and older 1 inhalation BIDsmaller inspiratory volumes which results in less dose reaching the Formoterol (Oxeze) Turbuhaler 6 or 12 mcg per doselower airways) the same dose can be used for all asthma medications Adults 1 inhalation of 6 or 12 mcg BID (max 48 mcg per day)at all ages. Children 6-16 1 inhalation of 6 or 12 mcg BID (max 24 mcg day)FP= Fluticasone propionate (GSK Canada Inc)
ORBUD= Budesonide (AstraZeneca Canada Inc) Advair (Serevent 50 mcg/Flovent 100, 250 & 500 mcg per dose) DiskusBDP= Beclomethosone dipropionate (3M Pharmaceuticals Canada) Adults and children 12 and older, 1 inhalation BID
Children 6-11 years of age, 1 inhalation BID Advair (Serevent 25 mcg/Flovent 125 & 250 per dose) MDI
Adults and children 12 and older, 1 or 2 inhalations BID Children 4 years of age and older, 1 or 2 inhalations BID
Symbicort (Oxeze 6 mcg/Pulmicort 100 & 200 mcg per dose) Turbuhaler Adults and children 12 years of age and older, 1 or 2 inhalations BID
Children 6 to 11 years of age, 1 or 2 inhalations BIDSECOND OPTION- Increase the inhaled corticosteriods (ICSs) to amoderate dosage as per chart or add in a leukotriene receptor antagonist. Montelukast (Singulair) 4, 5 & 10 mg chewable tablet Adults and children 15 years of age and older one 10 mg tablet daily
at bedtime Children 6 to 14 years of age one 5 mg tablet daily at bedtime Children 2 to 5 years of age one 4 mg tablet daily in the evening
Zarfirlukast (Accolate) 20 mg tablet
Adults and children 12 years of age and older two 20 mg tablets daily
THIRD OPTION consider theophylline, severe asthma may requireadditional treatment with Prednisone. If required to maintain control, referto the CPS for dosing requirements & refer to medical specialist.
Prednisone for acute exacerbations of asthma, use the followingdosages:
For ages 12 and over: 50 mg po daily for 3-10 days
For ages under 12: 1mg/kg po daily for 3-10 days (maximum dose: 2
mg/kg po daily)No Prednisone dose tapering required if less than 2 weeks
Treatment options from the Canadian Asthma Consensus Guidelines update 2003, medications updated as of January 12, 2006
Mcg/day (all ages)
Low Medium HighProduct
BUD TurbuhalerPulmicort
FP pMDI and spacerFlovent
FP DiskusBDP pMDI (HFA)
Q-varBUD wet nebulization
< 400
< 250
< 250< 250
< 1000
401 800
251 500
251 500251 500
1001- 2000
> 800
> 500
> 500> 500
> 2000
Asthma Severity based on treatment needed to obtain control Asthma Severity Symptoms Treatment required
Very mild Mild-infrequent None, or inhaled short-acting B-2 agonist rarely
Mild Well-controlled Short-acting B-2 agonist(occasionally) and low doseinhaled steroids
Moderate Well-controlled Short-acting B-2 agonist andlow to moderate doses ofinhaled steroids with orwithout add on therapy
Severe Well-controlled Short-acting B-2 agonist andhigh doses on inhaledsteroids and add on therapy
Very severe May be Short-acting B-2 agonist andcontrolled or not high doses of inhaledwell-controlled steroids and add on therapy
and oral steroids
8/7/2019 Asthma Clinical Guide
15/29
Asthma
Building Healthy LifestylesChinook Health Region 15
4. Management Strategies for Health Teams
a. Goals of Management
To maintain acceptable asthma control use nonpharmacologic andpharmacologic strategies. Asthma control is defined under KeyClinical Targets.
b. Key Clinical Targets
Criteria for asthma control
Parameter Frequency or value
Daytime symptoms less than 4 days/week
Night-time symptoms less than 1 night/week
Physical activity Normal
Exacerbations Mild, infrequent
Absence from work/school None
Need for short-acting beta-2 agonist Less than 4 doses/week*
FEV1.0 or PEF > 85% of personal bestIdeally 90%
PEF diurnal variation < 15% of diurnal variation
*May use 1 dose/day for prevention of exercise-induced symptoms
To be considered controlled asthma, all the above criteria mustbe met. If they are not met, it is then considered uncontrolledasthma.
Control can be achieved in uncontrolled asthma through patient
education, trigger avoidance and medications.
c. Non-Pharmacologic Strategies for Asthma
Environmental Control:
Elimination of exposure to environmental tobacco smoke (ETS)
Identification of asthma triggers and implement triggeravoidance strategies
Allergy testing to identify allergens to which a person issensitized; once these allergens are identified, steps shouldbe taken to eliminate or at least substantially reduce allergenexposure
Current recommendations for protecting against developmentof allergy and asthma in subsequent pregnancies and subsequentchildren:1. Elimination of exposure to ETS (includes during pregnancy)2. Promotion of exclusive breast feeding for at least 4 months3. For families with biparental atopy, maternal asthma or both,
it appears that there is substantive data to recommend againsthe presence of a cat or dog in the home
IMPORTANT! Medication should not be substituted forenvironmental control and trigger avoidance strategies.
Asthma Action Plan:
Devise a written action plan for the management ofexacerbations that includes medication adjustment in responseto changes in severity or frequency of symptoms, the need forsymptom relief medication or changes in PEF. Provide the
written document or ask an asthma educator to do so. Pleaserefer to Section 5, subsection a for a copy of the CHR Asthma
Action Plan.
Education and Follow-up:
Education is an essential component of asthma therapy and shouldbe offered to all patients. Educational interventions may be ofparticular benefit to patients with high asthma-related morbidity or
severe asthma and at the time of emergency department visits andadmissions to hospital.
All patients should self-monitor their asthma using symptoms orPEF or both
Ensure regular follow-up (every 6 months). Asthma controlcriteria should be assessed at each visit. Measurement ofpulmonary function, preferably spirometry, should be doneregularly in adults and children 6 years of age and older. Review
written action plan and medication required with an aim toreduce amount of medication while maintaining asthma control.
Smoking Cessation:
Smoking cessation interventions (4A model) should be offeredto patients who smoke, or parents of children with asthma whosmoke.
Influenza vaccination:
All patients with asthma should be encouraged to have an annuainfluenza vaccination, as well as any family members living withpatient (parents & siblings).
4. Management Strategies for Health Teams
8/7/2019 Asthma Clinical Guide
16/29
Asthma
Building Healthy LifestylesChinook Health Region 16
4. Management Strategies for Health Teams
Immunotherapy in Adults:
Immunotherapy is generally not recommended in the treatmentof asthma
Immunotherapy should not be used in place of avoidance ofenvironmental allergens
Immunotherapy with clinically relevant allergens may beconsidered if disease activity is inadequately controlled byavoidance of allergens and pharmacotherapy
Immunotherapy should be avoided while asthma is poorlycontrolled
Well-controlled asthma is not a contraindication forimmunotherapy for allergic rhinoconjunctivitis or insect venomhypersensitivity
Immunotherapy must be administered only by trained personnelin centres where there is medical supervision and resuscitativeequipment (for both children & adults)
Immunotherapy in Children: Although debate about the value of immunotherapy continues,
meta-analysis and review of immunotherapy support thepotential value of immunotherapy in childhood; earlyimmunotherapy may prevent development of asthma in childrensensitized to house dust mite allergen
Physicians should consider injection immunotherapy usingappropriate allergens for the treatment of allergic asthma only
when allergic component is well documented
Physicians should not recommend the use of injectionimmunotherapy in place of avoidance of environmental allergens
Physicians may consider injection immunotherapy in addition toappropriate environmental control and pharmacotherapy whenasthma control remains inadequate
Immunotherapy is not recommended when asthma is unstable
d. Pharmacologic Strategies for Asthma
First Line erapy:
Reliever medications rescue
Salbutamol (Ventolin) MDI 100 mcg per dose 1 or 2 inhalations as needed
Salbutamol (Ventolin) Diskus 200 mcg per dose Adults 1 inhalation as needed Children 6 years and older 1 inhalation as needed
Terbutaline (Bricanyl) Turbuhaler 0.5 mg per dose Adults 1 inhalation as needed Children 6 years and older 1 inhalation as needed
Salbutamol (Airomir) MDI 100 mcg per dose 1 to 2 inhalations as needed
AND
Inhaled Corticosteroids (ICSs) low dose maintenance
Regular use of low dose ICSs is currently the recommendedtreatment for persons with asthma of all ages, even for thosewith intermittent asthma symptoms
Physicians should recommend that children with frequentsymptoms, severe asthma exacerbations or both receive regular,not intermittent, treatment with ICSs
e use of intermittent treatment as a strategy for managementof intermittent asthma in childhood is not validated and requiresfurther research especially in very young children
For patients who cannot or will not use ICSs, leukotrienereceptor antagonists (LTRAs) should be the primary treatmentchoice, although they are less effective than low dose ICSs Fluticasone (Flovent) MDI 50, 125 & 250 mcg per dose
BID dosing most effective
Fluticasone (Flovent) Diskus 50, 100, 250, 500 mcg per dose BID dosing most effective
Budesonide (Pulmicort) Turbuhaler 100, 200 & 400 mcg perdose BID dosing most effective
Beclomethasone (Q-var) MDI 50 & 100 mcg per dose BID dosing most effective
8/7/2019 Asthma Clinical Guide
17/29
Asthma
Building Healthy LifestylesChinook Health Region 17
4. Management Strategies for Health Teams
Dose equivalencies for inhaled corticosteroids - ICSs (All ages)
Product
Low
Daily Dose (mcg/day)Moderate
High
BUD turbuhaler < 400 401 - 800 > 800
FP pMDI and spacer < 250 251 - 500 > 500FP Diskus < 250 251 - 500 > 500
BDP pMDI (HFA) < 250 251 - 500 > 500
BUD wet nebulization < 1000 1001 - 2000 > 2000
BDP= Beclomethasone dipropionate (Q-var)BUD= Budesonide (Pulmicort)FP= Fluticasone propionate (Flovent)* Note: Children will auto-scale their inhaled medication dose, (take proportionately smaller inspiratory volumes compared to adults, whichresults in less of the dispensed dose of inhaled medication reaching the lungs). e same dose can be used for all medications at all ages.
Add on erapy as Required:
If after reassessment of compliance with treatment, triggeravoidance strategies, inhaler technique and co-morbidities,asthma is not controlled by low dose ICSs, additional therapyshould be considered:
FIRST OPTION Add long-acting beta-2 agonist to existingtherapy of ICSs and short-acting beta-2 agonist, or replace ICSs
with a combination medication.
Salmeterol (Serevent) MDI 25 mcg per dose Adults 1 or 2 inhalations BID
Children 4 years of age and older 1 or 2 inhalations BID Salmeterol (Serevent) Diskus 50 mcg per dose Adults 1 inhalation BID Children 6 years of age and older 1 inhalation BID
Formoterol (Oxeze) Turbuhaler 6 or 12 mcg per dose Adults 1 inhalation of 6 or 12 mcg BID (max 48 mcg per
day) Children 6-16 1 inhalation of 6 or 12 mcg BID (max 24
mcg day)
OR
Advair (Serevent 50 mcg/Flovent 100, 250 & 500 mcg per dose)
Diskus Adults and children 12 and older, 1 inhalation BID Children 6-11 years of age, 1 inhalation BID
Advair (Serevent 25 mcg/Flovent 125 & 250 per dose) MDI Adults and children 12 and older, 1 or 2 inhalations BID Children 4 years of age and older, 1 or 2 inhalations BID
Symbicort (Oxeze 6 mcg/Pulmicort 100 & 200 mcg per dose)Turbuhaler Adults and children 12 years of age and older, 1 or 2
inhalations BID Children 6 to 11 years of age, 1 or 2 inhalations BID
SECOND OPTION- Increase the inhaled corticosteroids (ICSs)to a moderate dosage as per chart or add in a leukotriene receptorantagonist (LTRAs)
Montelukast (Singulair) 4, 5 & 10 mg chewable tablet Adults and children 15 years of age and older one 10 mg
tablet daily at bedtime Children 6 to 14 years of age one 5 mg tablet daily at
bedtime Children 2 to 5 years of age one 4 mg tablet daily in the
evening
Zarfirlukast (Accolate) 20 mg tablet
Adults and children 12 years of age and older two 20 mgtablets daily
THIRD OPTION Consider theophylline; severe asthma mayrequire additional treatment with prednisone. If required tomaintain control, refer to the CPS for dosing requirements andrefer to a medical specialist.
Prednisone:
For acute exacerbations of asthma, use the following dosages:
For ages 12 and over: 50 mg po daily for 3-10 days
For ages under 12: 1mg/kg po daily for 3-10 days (maximumdose: 2 mg/kg po daily)
No Prednisone dose tapering required if less than 2 weeks
8/7/2019 Asthma Clinical Guide
18/29
Asthma
Building Healthy LifestylesChinook Health Region 18
4. Management Strategies for Health Teams
Management of Acute Asthma Exacerbations (excluding ER andacute care facilities)
Acute asthma exacerbation is defined as deterioration of asthmacontrol that is not responding to B-2 agonist rescue treatment inthe usual manner or a sustained worsening of asthma symptomsleading to increased use of B-2 agonists as well as increased use ofmaintenance medications and/or supplementation with additionalmedicine. e following are loose criteria that can define an acuteasthma exacerbation:
Bronchodilator use 4 times/week (excluding 1 dose/day forexercise)
Nocturnal awakenings due to asthma 2 times/week
Daytime asthma symptoms 4 days/week
Recent absence from work or school due to asthma
Recent unscheduled physician visit due to asthma
Spirometry testing shows FEV1.0 < 80% of predicted normal
PEF tests fall below 80% of personal best value, or predictedvalue if personal best is not known
Studies have shown that the major cause (80%) of asthmaexacerbations is viral upper respiratory infections. With viralupper respiratory infections the inflammatory response tends tobe more neutrophilic than eosinophilic. Inhaled corticosteroidsmay not be effective during neutrophilic inflammatory responsesseen with viral upper respiratory infections.
Non-Pharmacologic Strategies:
Avoid contact with environmental tobacco smoke
Continue to avoid personal asthma triggers
Refer to personalized written asthma action plan as to how totemporarily modify asthma medications
Pharmacologic Strategies:
Prevention of asthma exacerbations needs to be the primarytarget of asthma treatment and ICSs. is can be accomplishedthrough regular use of ICSs as maintenance treatment forasthma.
Previous asthma guidelines have recommended the use of anaction plan to manage asthma exacerbations. Many of theseplans advocate a doubling of the dose of maintenance ICS as
one of the first steps in the management of worsening asthma.However, there are no randomized controlled trials to supportdoubling the dose of ICS on identification of exacerbations ofasthma.
2 recent studies (adult & pediatric populations) have providedevidence that early or impending asthma exacerbations arenot always effectively treated by doubling the dose of inhaledcorticosteroids at the first sign of an exacerbation. ese resultsapply to those patients with asthma who regularly use theirpreventer or controller medication as maintenance therapy when
well.
ere is some evidence for the potential benefit of a moresubstantial increase in the dose of ICS such as tripling orquadrupling the regular maintenance dose at the first sign of anasthma exacerbation.
e standard of care is that ICS dose should be increased duringan asthma exacerbation, but there is not enough good evidence
to make a generic recommendation as what dose to increase theICS from the maintenance dose during the exacerbation.
rough the COPD & Asthma Network of Alberta (CANA),as well as consulting local CHR specialists we have summarizedcurrent clinical practices utilized by both pediatric and adultrespiratory specialists throughout Alberta in managing acuteasthma exacerbations: If the client is on high doses of ICS for maintenance
(or maximum daily dosage for that client as decided byphysician), the clinical practice is to double the maintenancedose of ICS or maintain the current dose of ICS and add ina long-acting beta agonist (LABA) or leukotriene receptor
antagonist (LTRA) for a period of approximately 2 weeks. If client is on low to moderate doses of ICS for maintenance,
the clinical practice is to increase to the full dose of thespecific ICS for approximately 2 weeks, then return tomaintenance dose.
Full dose:
Fluticasone (Flovent) 500 1000 mcg/dayBeclamethasone (Q-Var) 400 800 mcg/dayBudesonide (Pulmicort) 800 1600 mcg/day
e clinical practice of many respiratory specialists is toincrease the dose of ICS at the first sign of an exacerbation
and whether the dose is doubled or quadrupled depends onthe clients maintenance dose as well as personal history ofexacerbations. ose who become ill quickly upon exposureto triggers treat more aggressively than those who generallymanage trigger exposure without significant incident.
If the asthma exacerbation is not responding to increaseddoses of ICS and add on therapy, a short course of oralprednisone should be considered. Recommended doses:
For ages 12 and over: 50 mg po daily for 3-10 days
For ages under 12: 1mg/kg po daily for 3-10 days(maximum dose: 2 mg/kg po daily)
No Prednisone dose tapering required if less than 2 weeks
Te above evidence is based on the opinions of those who have writtenand reviewed the asthma guidelines, based on their experience,knowledge of the relevant literature and discussion with their peers.
8/7/2019 Asthma Clinical Guide
19/29
Asthma
Building Healthy LifestylesChinook Health Region 19
Special Considerations:
Asthma in the Elderly
Diagnosis
A diagnosis of asthma should be more widely considered inelderly patients with dyspnea, wheezing or nocturnal cough.
Asthma may be difficult to diagnosis in the elderly because ofmisconceptions about its prevalence and also because olderpatients have diseases and disorders that mask the classic featuresof asthma.
Treatment
In the elderly patient with asthma, it is particularly important totake a careful medication history. Use of self-prescribed ASA hasbecome common and may go unrecognized. ASA and NSAIDSare commonly prescribed in the elderly and may cause late-on-set asthma. Oral and topical B-adrenergic blocking agents andother anti-arrhythmic agents, including verapamil and others
with acknowledged B-blocker potential, can exacerbate or causeasthma in those who are predisposed to the disease. Wheneverpossible, medications that might induce or aggravate asthmashould be withdrawn.
Special care should be taken to allow elderly patients with asthmato choose an inhaler device with which they are both comfortableand competent.
Measures should be taken to prevent osteoporosis in elderlypatients with asthma who require prolonged treatment with oralcorticosteroids.
Elderly patients with asthma require careful follow-up becausethey have an increased risk for exacerbations, which may be
related to impaired perception of their disease severity.
Asthma in Pregnancy
Asthma is present in 4 7 % of pregnant women and is therespiratory disorder that most frequently complicates pregnancy.
e course of asthma during pregnancy is variable and asthmacontrol may remain unchanged or become worse or improveand return to the pre-pregnancy state within 3 months afterparturition.
Overall, asthma control improves significantly in the last 4 weeksof pregnancy.
Asthmatic, pregnant women have been variably reported tohave an increased risk of pregnancy-induced hypertension, pre-eclampsia, caesarean section, placenta previa and antepartum orpostpartum hemorrhage.
Recommendations
Do not stop asthma therapy during pregnancy. Poorly controlledasthma may affect maternal comfort, safety and pregnancyoutcome for both mother and child. Several well designedstudies have shown fewer adverse infant and maternal outcomesthan those without therapy.
Physicians should discuss medication choices and the rationalefor treatment plan; they should emphasize that the treatmentprogram is considered to entail less risk than the uncontrolledillness that could result in its absence.
e use of systemic glucocorticosteriods for severe asthma,especially for prolonged periods, may be associated with a greater
risk of pre-eclampsia, antepartum or postpartum hemorrhage,low birth weight, preterm birth and hyperbilirubinemia.
Patients requiring systemic glucocorticosteroid therapy should beconsidered to be in a higher risk pregnancy.
Treatment
Avoidance of allergic and non-allergic triggering factors shouldbe the first form of therapy for asthma during pregnancy.
Treatment should take the same approach as the non-pregnantpatient and may include inhaled B-2 agonists, inhaledcorticosteroids, ipratropium bromide, cromolyn and systemicsteroids. eophylline may increase nausea and reflux and is less
desirable. ere is significantly less information about the effectsof long-acting B-2 agonists and leukotriene inhibitors and thereis less clinical experience with these drugs than with other classesof drugs. ese drugs should be used only for patients whoseasthma cannot be controlled using the more studied therapies.
For drugs with a longer history of usage, there tends to be moredata to support a lack of adverse effects. Use of most commonasthma medications (B-2 agonists, theophylline, cromolyn,inhaled glucocorticosteroids) during pregnancy has not beenshown to be associated with increased perinatal risks includingcongenital malformations.
Although no asthma medications can be considered proven
safe for use during pregnancy, the ones listed above are usedto prevent the potential direct and indirect consequences ofuncontrolled asthma.
e patient must be aware of the risks and benefits ofappropriate asthma control and must give her informed consentto the therapeutic approach recommended during pregnancy.
4. Management Strategies for Health Teams
8/7/2019 Asthma Clinical Guide
20/29
Asthma
Building Healthy LifestylesChinook Health Region 20
Inhalation Devices for drug delivery In Asthma
Metered Dose Inhalers (MDIs)
Metered Dose Inhalers can be used with any age group. A spacer orchamber should be used with children and elderly adults. A spacershould also be used if patient is receiving inhaled corticosteroids.
Under one year of age - a valved spacer and face mask should beused with MDI. (orange infant aerochamber with face mask)
From 2 to 6 years of age - a valved spacer and face mask shouldbe used with MDI. (yellow pediatric aerochamber with facemask)
More than 6 years of age - a valved spacer with a mouthpieceshould be used, rather than a face mask. (blue aerochamber)
Try to use a valved spacer with mouthpiece in children at theearliest age it becomes feasible. is will eliminate breathingthrough the nose and maximize the chance of increased airwaydeposition in the lungs. It has been clearly shown in children
that breathing through a mask via the nose decreases lungdeposition by up to 67% compared with breathing through amouthpiece using a jet nebulizer.
Dry Powder Inhalers (DPIs)
Dry Powder Inhalers can be used by most patients by the time theyreach 5 years of age. Spacer devices are not required with thesedevices. e two devices in Canada are the Turbuhaler and theDiskus inhaler.
MDIs vs Nebulizers:
Wet nebulizers for home use are rarely indicated in the
management of asthma at any age. e wet nebulizer device iscumbersome and expensive and for the amount of medicationdelivered the most costly of all methods.
ree meta-analyses of studies in children and adults evaluatingMDI and wet nebulization indicate that the use of MDI witha chamber or spacer is associated with a more rapid onset ofbronchodilation, shorter duration of emergency departmenttreatment, fewer side effects and greater patient preference. Morerapid and profound bronchodilation is achieved when sufficientdoses are given with an MDI plus spacer than when conventionaldoses are administered with a wet nebulizer.
Note: Proper inhaler technique must be taught to client. Referralto an asthma education program can ensure this is done. ere aredevices available to measure inspiratory flow rate to ensure patientcan adequately use a DPI.
4. Management Strategies for Health Teams
8/7/2019 Asthma Clinical Guide
21/29
Asthma
Building Healthy LifestylesChinook Health Region 21
5. Management Strategies for Patients / Clients
5. Management Strategies for Patients / Clients
ASTHMA ACTION PLANPatient Name:
(Last and First) _______________________________
Date of Birth: _________________________________
GREEN ZONE
YOUR ASTHMA IS IN GOOD CONTROL IF:
You do not wheeze, cough, feel tight or have
trouble breathing with your usual activities,
with exercise, or at night.
You require your reliever medicine less than
three times per week
Your peak flow is
between ________ and ________
(80% to 100% of personal best)
Action:
Avoid your personal asthma triggersAvoid tobacco smoke exposureYearly flu immunization
Watch for asthma symptoms
If you have symptoms with exercise take
___________ 15 minutes beforehand and remember
to warm up and cool down with exercise
Check your peak flow _______ per day
Controller(s): ____________________________
____________________________
Reliever(s): ____________________________
____________________________
Other Actions: ____________________________
YELLOW ZONE
YOUR ASTHMA CONTROL IS DECREASING IF:
You wheeze, cough, feel tight or have
trouble breathing with your usual activities,
with exercise or at night
You develop cold symptoms
You require your reliever medicine more than
three times per week
Your peak flow is
between ________ and ________
(60% to 80% of personal best)
Action:
Avoid your personal asthma triggers
Avoid tobacco smoke exposure
Check your peak flow _______ per day
if not already doing so
Controller(s): ____________________________
____________________________
Reliever(s): ____________________________
____________________________
Other Actions: ____________________________
____________________________
Seek medical attention if your asthma control isnot improving within 2 or 3 days
ORANGE ZONE
YOUR ASTHMA IS OUT OF CONTROL IF:
You wheeze, cough, feel tight or have
trouble breathing even at rest
Your symptoms are interrupting your sleep
You require your reliever medicine more than
four times in twenty four hours
Your peak flow is below _________
(60% of personal best)
Action:
Avoid your personal asthma triggers
Avoid tobacco smoke exposure
Check your peak flow _______ per day
if not already doing so
Controller(s): ____________________________
____________________________
Reliever(s): ____________________________
____________________________
Other Actions: ____________________________
____________________________
Seek medical attention if your asthma control isnot improving within 12-24 hours
RED ZONE
YOU ARE IN THE DANGER ZONE IF:
You are getting little relief to no relief in 20
to 30 minutes after your reliever medicine
You are struggling to breathe or having
trouble walking or talking
Your lips or fingernails are turning blue
Action:
Call 911 or go to the nearest emergency department
immediately
You can repeat your reliever medicine every ____
minutes times ____ doses while assistance is being
arranged
Prepared by:
______________________________M.D./RT/CAE Date: ____________
Physician Signature:____________________________________________
FC-532-01/06 adapted with permission: Alberta Lung Association White: Chart Canary: Patient Pink: Physician
Appointments:
Personal best or predicted peak flow _______
Update yearly and as needed
8/7/2019 Asthma Clinical Guide
22/29
Asthma
Building Healthy LifestylesChinook Health Region 22
8/7/2019 Asthma Clinical Guide
23/29
Asthma
Building Healthy LifestylesChinook Health Region 23
5. Management Strategies for Patients / Clients
YOU HAVE JUST BEEN TOLD THAT YOU ORYOUR CHILD HAS ASTHMA, NOW WHAT?
WHAT IS ASTHMA?
Asthma is an inflammatory disease of the small airways in the
lungs that results in recurring episodes of difficult breathing due tothe airways becoming more narrow (smaller) than normal. eseepisodes may occur quite often or may come and go intermittently.
Asthma ranges from very mild to severe.
WHAT ARE THE SYMPTOMS OF ASTHMA?
When the small airways in lungs begin to narrow, people withasthma usually notice some or all of the following problems:
Coughing
Wheezing
Chest tightness
Shortness of breath
Reduced ability to exercise
WHAT CAUSES AN ASTHMA EPISODE?(See diagram on back of this page)
First, a trigger is inhaled into the lungs and irritates the smallairways in the lungs.
Once the small airways are irritated, the insides of the airwaysbecome red, swollen and narrower than normal. If nothing isdone about the swelling it can get worse and people tend todevelop more asthma symptoms.
Due to the swelling, the small airways in the lungs become quitetwitchy. is causes the muscles on the outside of the airwayto tighten and narrow the airways even more. Breathing becomesmuch harder than normal at this point and could lead to aserious asthma episode.
Asthma episodes, like asthma itself, can range from mild tosevere. Severe asthma episodes can be life threatening and canresult in a hospital stay or even death. erefore, prevention ofepisodes is very important.
Common asthma triggers are smoke, colds, animal dander, dust,pollen, cold air and exercise. Please note that exercise shouldnot be avoided. If you or your child develops asthma symptoms
with exercise, it may be a sign that your or your childs asthmais poorly controlled. Contact a healthcare professional to learnhow to improve asthma control. Triggers vary from person toperson. Each person should learn about their own triggers andtry to prepare for them and avoid them when possible.
IS ASTHMA A LIFELONG CONDITION?
As a general rule, asthma diagnosed in childhood is a lifelong
condition. Asthma symptoms may diminish in adolescence, butcan often return in adulthood. People with the following factorsare most likely to have asthma that persists into adulthood:
A parent with asthma
A history of eczema (scaly red rashes on the skin)
Allergies or hay fever; allergic rhinitis (inflammation of the liningin the nose)
THE GOOD NEWS FOR PEOPLE WITH ASTHMA:
Researchers are constantly seeking a cure. In the meantime,asthma can be controlled. If asthma is well controlled, there isa low risk for a serious asthma episode and a person can be asactive as they like.
To control asthma you need to avoid contact with things thattrigger your asthma and use your asthma medications regularly asdirected by your doctor.
ere are people with well-controlled asthma who are OLYMPICATHLETES!
WHO WILL HELP YOU TO MANAGE YOUR ASTHMA?
Your family doctor will diagnose and help manage your or yourchilds asthma and should provide you with a written asthmaaction plan.
Your pharmacist can also provide helpful information aboutasthma and asthma medications.
Te Chinook Asthma Program is where you will meet withasthma educators who can perform breathing tests to make sureyour lungs are working at their best as well as provide you withinformation about asthma and asthma medications. e asthmaeducators will work with your doctor to develop a writtenasthma plan and ensure you have the tools and confidence to feelat ease managing your or your childs asthma.
To contact an asthma educator in your community, contact theBuilding Healthy Lifestyles toll-free number at 1-866-506-6654or 388-6654.
8/7/2019 Asthma Clinical Guide
24/29
Asthma
Building Healthy LifestylesChinook Health Region 24
What is asthma?
As the swelling in the airway increases,
the lining of the airway becomes very
sensitive and small muscles around it
start to twitch and tighten.
3 Inflammation ofairway and mucous
6 Emergency room visit
2 Something startsinflammation
5 Muscles aroundairway tighten
1 Normal airway =normal function
houu
wheeze
5. Management Strategies for Patients / Clients
Reprinted with permission from theAsthma Society of Canada
www.asthma.cawww.asthma-kids.ca
8/7/2019 Asthma Clinical Guide
25/29
Asthma
Building Healthy LifestylesChinook Health Region 25
5. Management Strategies for Patients / Clients
Client Checklist for Asthma
What to expect at each office visit with your family physician:
Assess asthma control:
Discuss frequency of asthma symptoms
Amount of rescue medication required (blue inhaler usage)
Review triggers and trigger avoidance strategies
Demonstrate use of inhaler device
Make or review a written asthma action plan
Discuss roles and use of asthma medications
Aim to reduce asthma medication dosage while maintaining proper control of asthma
Discuss any other concerns about asthma with your doctor
Tests & Measurements that should be done or discussed on a yearly basis,or as recommended by your family physician:
Lung function testing (spirometry)
Height and weight measurements
Screening for osteoporosis if on inhaled corticosteroids for asthma and you have the following risk factors:
Age > 60 years Postmenopausal state without hormone replacement therapy
Male impotence or infertility
Previous fractures with minor trauma
Family history of fractures (parental)
Past or current chronic glucocorticoid therapy
Smoking or alcoholism
Physical inactivity
Referral to an Asthma educator for education & evaluation
Vaccinations
Annual influenza vaccine
Ensure immunizations are up to date
8/7/2019 Asthma Clinical Guide
26/29
Asthma
Building Healthy LifestylesChinook Health Region 26
8/7/2019 Asthma Clinical Guide
27/29
Asthma
Building Healthy LifestylesChinook Health Region 27
6. Indications for a Referral to Medical Specialist or Specialty Program
6. Indications for a Referral to Medical Specialist or Specialty Program
a. and b. Indications for Referral to MedicalSpecialists and Specialty Programs
e following circumstances warrant a referral to an appropriate
specialist:
ere is doubt about the diagnosis of asthma
Factors, including aeroallergens and occupational exposures,could be involved and have not been properly evaluated; orsuspected occupational asthma
Asthma is severe according to severity rating criteria
ere is an apparent discrepancy between the severity ofsymptoms and success of treatment
ere has been a need for emergency treatment or hospitaladmission
Any persistent respiratory symptoms in infants (under 1 year ofage) and young children (age 1-6)
Normal spirometry tests and/or peak flows, but client requiresexcessive medication for symptom control or fails to respondto therapy after the clinician has confirmed compliance withtreatment and proper inhaler device technique
c. Local Contacts
In the CHR the primary care physicians would refer their adultpatients to see Dr. Wilde. Once the specialist has seen the client,they will book additional tests as they see fit.
Dr. E. Wilde, Specialist Internal & Respiratory Medicinephone 320-0633
In the CHR the primary care physicians would refer their pediatricpatients to see the following pediatricians:
Dr. K. Chan, Telephone 328-8101Dr. M. Harilal, Telephone 320-2236Dr. J. Holland, Telephone 320-7825
Or
e primary care physician could refer pediatric clients to theLethbridge Pediatric Asthma Clinic. A pediatrician will assess and
make recommendations for each child who attends the clinic. eprimary care physician would complete a referral form and fax it tothe Building Healthy Lifestyles Program.
Telephone: 388-6654 or 1-866-506-6654Fax: 317-0435
Key contacts in the CHR for Asthma:
Adult Specialists
Dr. Eric Wilde, Telephone 320-0633Pediatric Specialists
Dr. K. Chan, Telephone 328-8101Dr. M. Harilal, Telephone 320-2236Dr. J. Holland, Telephone 320-7825
Lethbridge Educators
Pediatric Asthma clinic, Telephone 388-6180 Adult Asthma Clinic, Telephone 388-6180
Rural Educators
Taber Asthma program, Telephone 223-3525Cardston Telephone 653-4411Magrath Telephone 758-4411Pincher Creek, Telephone 627-1234Crowsnest Pass, Telephone 562-2831Fort Macleod, Telephone 553-5311Raymond, Telephone 752-4561Milk River, Telephone 647-3500Picture Butte, Telephone 732-4762
By contacting Building Healthy Lifestyles 388-6654 or1-866-506-6654 an appointment can be booked for the patientand BHL will notify the appropriate asthma educator.
Clinical Guides are available on-line at:
www.chinookprimarycarenetwork.ab.ca/extranet/resources/guides.php
8/7/2019 Asthma Clinical Guide
28/29
Asthma
Building Healthy LifestylesChinook Health Region 28
8/7/2019 Asthma Clinical Guide
29/29
Asthma7. References
7. References
a. Evidence1. Becker, Allan, MD; Berube, Denis, MD; Montgomery, Mark, MD; Sears, Malcolm, MD; Spier, Sheldon, MD; on behalf of
the Canadian Pediatric Asthma Consensus Guidelines 2003 (updated to December 2004) Supplement to CMAJ 2005; 173(6 suppl): S1-S56
2. Boulet,Louis-Philippe, MD; Becker, Allan, MD; Berube, Denis, MD; Beveridge,Robert, MD; Ernst, Pierre MD; on behalfof the Canadian Asthma Consensus group. Canadian Asthma Consensus Report 1999. Supplement to CMAJ 1999; 161(11 suppl)
3. British Columbia Guidelines & Protocols Advisory Committee, Diagnosis and Management of Asthma July 1, 2003
4. FitzGerald JM, Becker A, Sears MR, et al. Doubling the dose of budesonide versus maintenance treatment in asthmaexacerbations. orax 2004;59:550-6
5. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlledtrial. Lancet 2002; 360:1715-21
6. Harrison TW, Oborne J, Newton S, et al. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations:randomised controlled trial. Lancet 2004;363:271-5
7. Jarjour NN, Gern JE, Kelly EA, et al. e effect of an experimental rhinovirus 16 infection on bronchial lavage neutrophils.J Allergy Clin Immunol 2000;105:1169-77
8. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in9-11 year old children. BMJ 1995;310:1225-9
9. Lemiere,C; Bai,T; Balter, M, et al, on behalf of the Canadian Adult Consensus group of the Canadian oracic Society.Adult Asthma Consensus guidelines update 2003. Can Respir J 2004; 11 (Suppl A); 9A 18A
10. Respiratory Division, Cardio-Respiratory diseases and diabetes bureau, laboratory centre for disease control, Health Canada.e national asthma control task force. e prevention and management of asthma in Canada 2000
b. On-line Resources1. Canadian Lung Association www.lung.ca
2. Canadian oracic Society www.lung.ca/cts/3. COPD & Asthma Network of Alberta (CANA) www.canahome.org
4. Family Physicians Airways Group of Canada www.fpagc.com
5. Canadian Network for Asthma Care (CNAC) www.cnac.net
6. Child Asthma Network iCan www.calgaryhealthregion.ca/ican/
7. National Institute of Health www.nhlbi.nih.gov
8. Canadian Society of Allergy & Clinical Immunology www.csaci.medical.org
9. Global Initiative for Asthma www.ginaasthma.com
10. Calgary Allergy Network www.calgaryallergy.ca
11. American Academy of Allergy, Asthma & Immunology www.aaaai.org
12. Asthma Society of Canada www.asthma.ca
Available CHR Resources Winning with Asthma www.chr.ab.ca